Sign in or create an account to add this stock to your watchlist.
About Natera (NASDAQ:NTRA)
Natera, Inc., a diagnostics company, provides preconception and prenatal genetic testing services. It primarily offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus typically with a blood draw from the mother; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases that could be passed on to the carrier's children; and Spectrum pre-implantation genetic screening and Spectrum pre-implantation genetic diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle. The company also provides Anora Products of Conception test to analyze fetal chromosomes to understand the cause of miscarriage; and non-invasive paternity testing products to determine paternity by analyzing the fragments of fetal deoxyribonucleic acid in a pregnant mother's blood and a blood sample from the alleged father. In addition, it offers Constellation, a cloud-based software product that allows laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics in order to validate and launch tests. The company offers products through its direct sales force, as well as through a network of approximately 70 laboratory and distribution partners in the United States and internationally. The company was formerly known as Gene Security Network, Inc. and changed its name to Natera, Inc. in 2012. Natera, Inc. was founded in 2003 and is headquartered in San Carlos, California.
Industry, Sector and Symbol
Industry Medical laboratories
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:NTRA
CUSIPN/A
Phone650-249-9090
Debt
Debt-to-Equity Ratio-18.90
Current Ratio1.80
Quick Ratio1.68
Price-To-Earnings
Trailing P/E Ratio-4.74
Forward P/E Ratio-5.55
P/E GrowthN/A
Sales & Book Value
Annual Sales$210.94 million
Price / Sales2.94
Cash FlowN/A
Price / CashN/A
Book Value($0.07) per share
Price / Book-162.43
Profitability
EPS (Most Recent Fiscal Year)($2.40)
Net Income$-136,310,000.00
Net Margins-58.84%
Return on Equity-752.93%
Return on Assets-66.23%
Miscellaneous
Employees893
Outstanding Shares54,510,000
Natera (NASDAQ:NTRA) Frequently Asked Questions
What is Natera's stock symbol?
Natera trades on the NASDAQ under the ticker symbol "NTRA."
How were Natera's earnings last quarter?
Natera Inc (NASDAQ:NTRA) posted its quarterly earnings results on Tuesday, May, 8th. The medical research company reported ($0.61) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.60) by $0.01. The medical research company had revenue of $62.34 million for the quarter, compared to analysts' expectations of $54.86 million. Natera had a negative net margin of 58.84% and a negative return on equity of 752.93%. The firm's revenue for the quarter was up 26.2% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.70) EPS. View Natera's Earnings History.
What price target have analysts set for NTRA?
5 Wall Street analysts have issued 12 month price objectives for Natera's stock. Their forecasts range from $12.00 to $16.00. On average, they anticipate Natera's share price to reach $14.75 in the next year. View Analyst Ratings for Natera.
Who are some of Natera's key competitors?
Some companies that are related to Natera include Genomic Health (GHDX), RadNet (RDNT), Invitae (NVTA), CareDx (CDNA), Enzo Biochem (ENZ), Veracyte (VCYT), Miragen Therapeutics (MGEN), Celcuity (CELC), Psychemedics (PMD), Fulgent Genetics (FLGT), First Choice Healthcare Solutions (FCHS), Cancer Genetics (CGIX), Biocept (BIOC), OpGen (OPGN) and Cord Blood America (CBAI).
Who are Natera's key executives?
Natera's management team includes the folowing people:
- Dr. Matthew Rabinowitz, Co-Founder, CEO, Pres & Chairman (Age 45)
- Mr. Michael Brophy, Chief Financial Officer (Age 38)
- Mr. Steve Chapman, Chief Operating Officer (Age 39)
- Mr. Jonathan Sheena M.Eng., Co-Founder, Chief Technology Officer and Director (Age 45)
- Mr. Daniel Rabinowitz L.L.M., LL.M., Corp. Sec. and Gen. Counsel
When did Natera IPO?
(NTRA) raised $101 million in an initial public offering (IPO) on Thursday, July 2nd 2015. The company issued 6,300,000 shares at $15.00-$17.00 per share. Morgan Stanle, Cowen and Company and Piper Jaffray acted as the underwriters for the IPO and Baird and Wedbush Pacgrow were co-managers.
Has Natera been receiving favorable news coverage?
Media coverage about NTRA stock has trended positive on Friday, Accern reports. Accern scores the sentiment of news coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Natera earned a news impact score of 0.42 on Accern's scale. They also gave press coverage about the medical research company an impact score of 45.30 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company's share price in the near term.
Who are Natera's major shareholders?
Natera's stock is owned by many different of retail and institutional investors. Top institutional investors include Sofinnova Ventures Inc (5.69%), Kornitzer Capital Management Inc. KS (1.08%), Northern Trust Corp (0.69%), Asymmetry Capital Management L.P. (0.60%), Millennium Management LLC (0.58%) and Schwab Charles Investment Management Inc. (0.32%). Company insiders that own Natera stock include Claremont Creek Partners Fund, Herm Rosenman, Jonathan Sheena, Matthew Rabinowitz, Michael Burkes Brophy, Roelof Botha and Steven Leonard Chapman. View Institutional Ownership Trends for Natera.
Which major investors are selling Natera stock?
NTRA stock was sold by a variety of institutional investors in the last quarter, including Citadel Advisors LLC, Principal Financial Group Inc. and Principal Financial Group Inc.. Company insiders that have sold Natera company stock in the last year include Claremont Creek Partners Fund, Jonathan Sheena, Michael Burkes Brophy and Steven Leonard Chapman. View Insider Buying and Selling for Natera.
Which major investors are buying Natera stock?
NTRA stock was bought by a variety of institutional investors in the last quarter, including Sofinnova Ventures Inc, Millennium Management LLC, Asymmetry Capital Management L.P., Kornitzer Capital Management Inc. KS, Schwab Charles Investment Management Inc., A.R.T. Advisors LLC, Trexquant Investment LP and Swiss National Bank. View Insider Buying and Selling for Natera.
How do I buy shares of Natera?
Shares of NTRA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Natera's stock price today?
One share of NTRA stock can currently be purchased for approximately $11.37.
How big of a company is Natera?
Natera has a market capitalization of $635.62 million and generates $210.94 million in revenue each year. The medical research company earns $-136,310,000.00 in net income (profit) each year or ($2.40) on an earnings per share basis. Natera employs 893 workers across the globe.
How can I contact Natera?
Natera's mailing address is 201 INDUSTRIAL ROAD SUITE 410, SAN CARLOS CA, 94070. The medical research company can be reached via phone at 650-249-9090.
MarketBeat Community Rating for Natera (NTRA)
MarketBeat's community ratings are surveys of what our community members think about Natera and other stocks. Vote "Outperform" if you believe NTRA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NTRA will underperform the S&P 500 over the long term. You may vote once every thirty days.
Natera (NASDAQ:NTRA) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
5 Wall Street analysts have issued ratings and price targets for Natera in the last 12 months. Their average twelve-month price target is $14.75, suggesting that the stock has a possible upside of 29.73%. The high price target for NTRA is $16.00 and the low price target for NTRA is $12.00. There are currently 5 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 3.00 | 3.00 | 3.00 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $14.75 | $14.75 | $14.3333 | $15.00 |
| Price Target Upside: | 29.73% upside | 67.61% upside | 45.52% upside | 60.60% upside |
Natera (NASDAQ:NTRA) Consensus Price Target History
Natera (NASDAQ:NTRA) Analyst Ratings History
Show:
(Data available from 5/25/2016 forward)
Natera (NASDAQ:NTRA) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Natera (NASDAQ NTRA) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 13.18%
Institutional Ownership Percentage: 72.28%
Natera (NASDAQ NTRA) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 5/16/2018 | Claremont Creek Partners Fund | Major Shareholder | Sell | 25,027 | $11.59 | $290,062.93 | |  |
| 5/14/2018 | Claremont Creek Partners Fund | Major Shareholder | Sell | 37,540 | $11.48 | $430,959.20 | | |
| 3/26/2018 | Michael Burkes Brophy | CFO | Sell | 1,449 | $9.74 | $14,113.26 | 4,468 | |
| 3/26/2018 | Steven Leonard Chapman | COO | Sell | 1,997 | $9.74 | $19,450.78 | 4,468 | |
| 9/6/2017 | Jonathan Sheena | Insider | Sell | 120,000 | $12.54 | $1,504,800.00 | 533,208 | |
| 4/5/2017 | Herm Rosenman | Director | Sell | 1,809 | $8.55 | $15,466.95 | 42,950 | |
| 1/4/2017 | Herm Rosenman | CFO | Sell | 1,849 | $11.87 | $21,947.63 | 33,409 | |
| 12/22/2016 | Jonathan Sheena | Insider | Sell | 16,213 | $12.00 | $194,556.00 | 645,972 | |
| 12/20/2016 | Jonathan Sheena | Insider | Sell | 1,087 | $12.00 | $13,044.00 | 630,846 | |
| 12/13/2016 | Jonathan Sheena | Insider | Sell | 2,700 | $12.00 | $32,400.00 | 632,459 | |
| 12/6/2016 | Herm Rosenman | CFO | Sell | 1,828 | $11.83 | $21,625.24 | 30,237 | |
| 12/5/2016 | Matthew Rabinowitz | CEO | Sell | 14,021 | $12.02 | $168,532.42 | 1,888,644 | |
| 12/1/2016 | Matthew Rabinowitz | CEO | Sell | 56,072 | $12.01 | $673,424.72 | 1,942,572 | |
| 11/28/2016 | Matthew Rabinowitz | CEO | Sell | 146,756 | $12.50 | $1,834,450.00 | 2,020,876 | |
| 11/21/2016 | Jonathan Sheena | Insider | Sell | 32,505 | $12.00 | $390,060.00 | 630,165 | |
| 11/3/2016 | Herm Rosenman | CFO | Sell | 1,852 | $7.98 | $14,778.96 | | |
| 10/6/2016 | Herm Rosenman | CFO | Sell | 1,773 | $11.53 | $20,442.69 | 22,051 | |
| 10/5/2016 | Jonathan Sheena | Insider | Sell | 1,600 | $12.00 | $19,200.00 | 617,151 | |
| 9/6/2016 | Herm Rosenman | CFO | Sell | 1,822 | $10.21 | $18,602.62 | 18,873 | |
| 8/2/2016 | Herm Rosenman | CFO | Sell | 1,833 | $12.98 | $23,792.34 | 15,706 | |
| 7/6/2016 | Herm Rosenman | CFO | Sell | 1,824 | $12.10 | $22,070.40 | 12,530 | |
| 7/1/2016 | Matthew Rabinowitz | CEO | Sell | 104,892 | $12.14 | $1,273,388.88 | 2,167,354 | |
| 6/19/2016 | Jonathan Sheena | CTO | Sell | 188,442 | $11.94 | $2,249,997.48 | 598,420 | |
| 6/19/2016 | Matthew Rabinowitz | CEO | Sell | 732,831 | $11.94 | $8,750,002.14 | 2,876,595 | |
| 6/19/2016 | Roelof Botha | Director | Buy | 837,521 | $11.94 | $10,000,000.74 | | |
| 6/2/2016 | Herm Rosenman | CFO | Sell | 1,806 | $12.04 | $21,744.24 | 9,336 | |
| 2/1/2016 | Jonathan Sheena | CTO | Sell | 10,000 | $8.03 | $80,300.00 | 615,551 | |
| 1/5/2016 | Matthew Rabinowitz | CEO | Sell | 54,683 | $10.37 | $567,062.71 | 2,762,777 | |
| 1/4/2016 | Jonathan Sheena | CTO | Sell | 25,000 | $10.06 | $251,500.00 | 622,551 | |
| 12/31/2015 | Matthew Rabinowitz | CEO | Sell | 111,513 | $10.83 | $1,207,685.79 | 2,817,460 | |
| 12/29/2015 | Jonathan Sheena | CTO | Sell | 50,000 | $10.44 | $522,000.00 | 640,051 | |
| 12/29/2015 | Matthew Rabinowitz | CEO | Sell | 83,804 | $10.62 | $889,998.48 | 2,928,973 | |
| 7/8/2015 | James Healy | Director | Buy | 350,000 | $18.00 | $6,300,000.00 | | |
| 7/2/2015 | James Healy | Director | Buy | 400,000 | $22.81 | $9,124,000.00 | | |
(Data available from 1/1/2013 forward)
Natera (NASDAQ NTRA) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Naturally Splendid Engages Doctor as Qualified Person In Charge and Advisory Board Member
www.nasdaq.com - May 23 at 9:18 AM |
 | OpGen (OPGN) versus Natera (NTRA) Financial Review
www.americanbankingnews.com - May 19 at 3:37 PM |
| Insider Selling: Natera Inc (NTRA) Major Shareholder Sells 25,027 Shares of Stock
www.americanbankingnews.com - May 17 at 8:15 PM |
| $60.32 Million in Sales Expected for Natera Inc (NTRA) This Quarter
www.americanbankingnews.com - May 16 at 3:46 AM |
| Claremont Creek Partners Fund Sells 37,540 Shares of Natera Inc (NTRA) Stock
www.americanbankingnews.com - May 15 at 10:10 PM |
| Natera (NTRA) Lowered to Hold at ValuEngine
www.americanbankingnews.com - May 15 at 11:34 AM |
| Analysts Expect Natera Inc (NTRA) to Post -$0.53 EPS
www.americanbankingnews.com - May 14 at 9:35 AM |
| Q2 2018 EPS Estimates for Natera Inc Reduced by Piper Jaffray (NTRA)
www.americanbankingnews.com - May 11 at 8:35 AM |
| Natera Inc (NTRA) Receives Average Rating of "Buy" from Analysts
www.americanbankingnews.com - May 10 at 4:37 PM |
 | Edited Transcript of NTRA earnings conference call or presentation 8-May-18 8:30pm GMT
finance.yahoo.com - May 10 at 9:49 AM |
| Morgan Stanley Raises Natera (NTRA) Price Target to $16.00
www.americanbankingnews.com - May 9 at 4:43 PM |
| Natera (NTRA) Posts Quarterly Earnings Results, Misses Estimates By $0.01 EPS
www.americanbankingnews.com - May 9 at 1:43 PM |
| Natera: 1Q Earnings Snapshot
finance.yahoo.com - May 9 at 9:39 AM |
| Contrasting Natera (NTRA) & Quest Diagnostics (DGX)
www.americanbankingnews.com - May 3 at 9:43 PM |
| Natera (NTRA) Stock Rating Upgraded by ValuEngine
www.americanbankingnews.com - May 2 at 11:36 PM |
| Natera (NTRA) to Release Earnings on Monday
www.americanbankingnews.com - May 2 at 8:32 PM |
 | Natera Inc. Announces First Quarter 2018 Earnings Conference Call
www.prnewswire.com - May 1 at 6:12 PM |
| Head-To-Head Comparison: Fulgent Genetics (FLGT) versus Natera (NTRA)
www.americanbankingnews.com - May 1 at 3:12 PM |
| Natera Inc (NTRA) Expected to Post Quarterly Sales of $55.39 Million
www.americanbankingnews.com - April 28 at 2:10 AM |
| Natera Inc (NTRA) Expected to Post Earnings of -$0.54 Per Share
www.americanbankingnews.com - April 26 at 9:20 PM |
| Natera (NTRA) Upgraded by BidaskClub to "Hold"
www.americanbankingnews.com - April 21 at 7:24 AM |
| ValuEngine Downgrades Natera (NTRA) to Strong Sell
www.americanbankingnews.com - April 16 at 7:35 PM |
| Natera (NTRA) Downgraded to Hold at BidaskClub
www.americanbankingnews.com - April 16 at 8:18 AM |
| Natera Inc (NTRA) Given Consensus Rating of "Hold" by Brokerages
www.americanbankingnews.com - April 15 at 11:29 AM |
| Natera (NTRA) & Its Peers Financial Review
www.americanbankingnews.com - April 15 at 7:21 AM |
| Natera (NTRA) Downgraded by BidaskClub
www.americanbankingnews.com - April 14 at 5:18 PM |
| Natera (NTRA) vs. The Competition Head-To-Head Comparison
www.americanbankingnews.com - April 14 at 7:43 AM |
| Natera to Present Successful Results at AACR from Bladder and Colon Cancer Studies
finance.yahoo.com - April 13 at 4:21 PM |
| Natera (NTRA) Upgraded by Zacks Investment Research to "Buy"
www.americanbankingnews.com - April 11 at 5:35 PM |
| Natera (NTRA) Lifted to Sell at ValuEngine
www.americanbankingnews.com - April 11 at 3:58 PM |
| Natera (NTRA) Upgraded to "Hold" at ValuEngine
www.americanbankingnews.com - April 11 at 12:04 PM |
| Natera (NTRA) Rating Increased to Sell at BidaskClub
www.americanbankingnews.com - April 11 at 11:01 AM |
| Natera Inc (NTRA) Expected to Post Quarterly Sales of $55.51 Million
www.americanbankingnews.com - April 11 at 1:44 AM |
| Financial Analysis: Natera (NTRA) & Its Competitors
www.americanbankingnews.com - April 10 at 7:09 PM |
| Natera To Present New Data at ACMG Annual Meeting
finance.yahoo.com - April 10 at 10:01 AM |
| Natera Inc (NTRA) Expected to Announce Earnings of -$0.54 Per Share
www.americanbankingnews.com - April 9 at 11:17 PM |
 | Benzinga's Top Upgrades, Downgrades For April 9, 2018
www.benzinga.com - April 9 at 9:51 AM |
| Natera Appoints Paul R. Billings, MD, Ph.D., as Chief Medical Officer
www.prnewswire.com - April 9 at 9:51 AM |
| Natera Appoints Paul R. Billings, M.D., Ph.D., as Chief Medical Officer
finance.yahoo.com - April 9 at 9:51 AM |
| Natera (NTRA) Research Coverage Started at Craig Hallum
www.americanbankingnews.com - April 9 at 8:25 AM |
| Critical Survey: Natera (NTRA) & Its Rivals
www.americanbankingnews.com - April 8 at 3:08 AM |
| Natera (NTRA) Downgraded by Zacks Investment Research to Hold
www.americanbankingnews.com - April 4 at 11:26 PM |
| Head-To-Head Review: Natera (NTRA) and The Competition
www.americanbankingnews.com - April 4 at 3:06 AM |
| Critical Review: Natera (NTRA) & Its Competitors
www.americanbankingnews.com - April 1 at 1:16 PM |
| Contrasting Natera (NTRA) and Its Competitors
www.americanbankingnews.com - March 31 at 11:16 PM |
 | Form 4 Natera, Inc. For: Mar 26 Filed by: Brophy Michael Burkes
www.streetinsider.com - March 29 at 10:03 AM |
 | Why Hemp Could Become the Next Biggest Cash Crop and How to Profit -- CFN Media
globenewswire.com - March 29 at 10:03 AM |
| Natera Inc (NTRA) CFO Michael Burkes Brophy Sells 1,449 Shares
www.americanbankingnews.com - March 28 at 11:10 PM |
| Insider Selling: Natera Inc (NTRA) COO Sells 1,997 Shares of Stock
www.americanbankingnews.com - March 28 at 11:10 PM |
| Natera (NTRA) Downgraded to Sell at Zacks Investment Research
www.americanbankingnews.com - March 26 at 9:18 PM |
Natera (NASDAQ:NTRA) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Natera (NASDAQ:NTRA) Income Statement, Balance Sheet and Cash Flow Statement
Natera (NASDAQ NTRA) Stock Chart for Friday, May, 25, 2018
Loading chart…
